Skip to main content
Equibles
RPID logo

RPID · Rapid Micro Biosystems, Inc.

Track RPID — free

Use RPID with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.57 -0.04 (-2.48%) At close · Aug 28
Rebalance outlook locked
Market Cap
$78.50M
Shares
50.16M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.57 Open$1.62 Day$1.55–1.63 52W close$1.55–4.68 Avg vol 30d217K Short int844K · 1.7% float · 3.0d Short vol30% Last earningsAug 7, 2026 DataJul 2021–Aug 2026 Filing10-Q · Aug 7

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 7, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −44%
      below
      Price vs 50-day avg −15%
      below
      RSI (14) 34
      neutral
      MACD trend Negative
      52-week position 1%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −26%
      trailing
      6-month return −63%
      trailing
      YTD return −46%
      this year
      Relative strength −76%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $2 › 200d $3 — 200d above 50d
      Institutional flow Distributing
      -28% holders QoQ · +5 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      1.68% of float · ▲ +2.2% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      33 holders — mid 3-yr range
      Squeeze score 49
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +20%
      Y/Y
      EPS growth +3%
      Y/Y
      Free cash flow $-31.9M
      Balance sheet $27.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 83%
      annualized · 1-yr
      Max drawdown −67%
      past year
      ATR 7.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 8 of last 8
      Latest guidance · from the Earnings Call filed Aug 7, 2026
      full year 2026
      Total revenue Maintained $37M – $41M
      May 13, 2026 $37M – $41M changed to Aug 7, 2026 $37M – $41M
      prior FY $33.59M midpoint +16.1% Y/Y
      Capital expenditures Initiated $1M
      Total gross margin Initiated 20%
      Non-cash expenses Initiated $8M
      Operating expenses Initiated $51M – $53M
      Service margin Initiated 45% – 50%
      Depreciation and amortization expense Initiated $3M
      CapEx Lowered $1M
      Mar 31, 2026 $2M changed to Aug 7, 2026 $1M
      Interest income Maintained $1M
      Mar 31, 2026 $1M changed to Aug 7, 2026 $1M
      Stock compensation expense Initiated $5M
      Interest expense Initiated $2M
      third quarter 2026
      Gross margin at least 20%
      Q3
      Gross margin percentage at least 20%
      Revenue at least $9.5M
      prior qtr $8.05M midpoint +18.0% QoQ
      annually beginning in 2027
      Expenses and cash usage reduction $3M
      remainder of 2026
      Expenses and cash usage reduction $1M
      exiting 2028
      Gross margin at least 50%
      Prior guidance period ended · from the Earnings Call filed Mar 31, 2026
      Revenue · Q2 at least $7.7M
      Guided vs delivered · last 8 settled
      Revenue Q2
      guided at least $7.7M
      $8.05M In line
      Total revenue full year 2025
      guided at least $33M
      $33.59M In line
      Total revenue second quarter
      guided at least $6M
      $6.62M In line
      Total revenue full-year 2024
      guided at least $27M
      $28.05M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −44% Bearish
      Price vs 50-day avg
      −15% Bearish
      RSI (14)
      34 Neutral
      MACD trend
      Negative Bearish
      52-week position
      1% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $2 › 200d $3 — 200d above 50d
      Institutional flow Distributing
      -28% holders QoQ · +5 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      1.68% of float · ▲ +2.2% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      33 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $2 Now $2 · 1% Range high $5
      vs 200-day avg -44% vs 50-day avg -15%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Cumulative systems placed 200 Three Months Ended June 30, 2026 filing —
      Cumulative systems validated 169 Three Months Ended June 30, 2026 filing —
      Non-GAAP adjusted EBITDA loss non-GAAP $10.3M Q2 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net loss -12.92M
      -140K Interest income
      +646K Interest expense
      +50K Other expense, net
      +45K Income tax expense
      +674K Depreciation and amortization
      +1.32M Stock-based compensation
      = Non-GAAP adjusted EBITDA loss -10.33M
      Product and service revenue — total $8.05M Three Months Ended June 30, 2026 filing —
      recurring revenue as a percent of total revenue 63% Q2 2026 —
      Recurring revenue as a percentage of total revenue 62.7% Three Months Ended June 30, 2026 filing —
      Systems placed in period 4 Three Months Ended June 30, 2026 filing —
      Systems validated in period 9 Three Months Ended June 30, 2026 filing —
      Customer systems validated 18 full year 2025 —
      Gross margin percentage 3% full year 2025 —
      Growth Direct systems placed 28 full year 2025 —
      Non-GAAP adjusted total gross margin percentage non-GAAP 6% full year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      RPID
      Rapid Micro Biosystems, Inc.
      this stock
      		$78.50M -45.9% +19.7% — 1.7%
      ABT
      Abbott Laboratories
      		 $195.90B -10.2% +5.7% 31.5 1.2%
      SYK
      Stryker Corp
      		 $127.12B -5.9% +11.2% 34.3 1.8%
      MDT
      Medtronic plc
      		 $115.17B -5.0% +8.4% 24.1 1.1%
      BSX
      Boston Scientific Corp
      		 $67.88B -50.9% +12.5% 19.0 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      33
      % held
      34.7%
      Net QoQ
      +1.6M sh
      Top holder
      Bain Capital Life Science…
      Held Float
      View
      Held by Funds
      Fund positions
      21
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      843.8K
      Days to cover
      3.0d
      Change
      +18.1K sh
      View
      Short Volume
      Short vol %
      30%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.9K
      Value
      $3.9K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      44.2%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $33.6M
      Net income (FY)
      $-47.1M
      EPS diluted
      $-1.05
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 7, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $17.0K
      Shares
      10.0K
      Filed
      Jul 8, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 7, 2026
      View
      Investor Relations
      Latest news
      Rapid Micro Biosystems Reports Se…
      Published
      Aug 7, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      RPID -6.6% -26.3% -62.6% -26.3% -45.9%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY -7.0% -29.3% -76.1% -29.3% -58.7%
      Key facts CIK 1380106 CUSIP 75340L104 13F (30d) 34 filings 33 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)